Patient characteristic | n | % |
---|---|---|
HER2/neu overexpressiona | ||
Score 2+ | 31 | 30.1 |
Score 3+ | 72 | 69.9 |
Treatment | ||
Single-agent trastuzumab | 13 | 12.6 |
Trastuzumab + taxane | 52 | 50.5 |
Trastuzumab + vinorelbine | 11 | 10.7 |
Trastuzumab + taxane + megestrol acetate | 6 | 5.8 |
Trastuzumab + taxane + tamoxifen | 5 | 4.8 |
Trastuzumab + bevacizumab | 5 | 4.8 |
Trastuzumab + taxane + carboplatin | 4 | 3.9 |
Trastuzumab + taxane + CMF | 3 | 2.9 |
Trastuzumab + erlotinib | 2 | 1.9 |
Trastuzumab + doxorubicin + cyclophosphamide | 2 | 1.9 |